Thermo Fisher launches a new extended gene therapy portfolio to support more effective adeno-associated virus preparation

Recently, Thermo Fisher Scientific has launched a set of solutions that support the production of adeno-associated virus (AAV) to help gene therapy developers quickly and efficiently scale production

AAV is a non-pathogenic virus with the ability to infect all stages of cell growth and has become the first choice for gene therapy

Betty Woo, Vice President and General Manager of Cell and Gene Therapy, Thermo Fisher said: "Although gene therapy has great promise, robustness and yield continue to pose challenges in the production process

The Gibco viral vector HEK media panel is part of an ever-expanding portfolio that covers a wide range of HEK293 cell types, independent of specific transfection reagents or technology

The application of biological system resDNASEQ to quantify plasmid DNA-Kanamycin resistance gene kit* provides an integrated solution for accurate and rapid measurement of residual plasmid DNA

Thermo Scientific POROS CaptureSelect AAV affinity purification resin*, the latest combination of viral vector solutions, including the leading POROS CaptureSelect AAV8, AAV9 and AAVX affinity purification resins and the POROS CaptureSelect AAVX evolutionary column, by reducing purification steps and providing scalability, Maximizing process consistency, efficiency and productivity can significantly improve the downstream processing of viral vectors

CaptureSelect ligand technology, combined with the macroporous structure of POROS beads, can efficiently purify large biomolecules, such as viral vectors

For more information about Thermo Fisher's gene therapy program, please visit our website

*The intended use of the product is different

https://thermofisher.